RA0375

antibody from Oursmab

Targeting: IL2RA CD25, IDDM10, IL2R

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0375

Provider

Oursmab

Product name

Daclizumab (Biosimilar Reference Antibody) (IL2RA)

Antibody type

Monoclonal

Description

Daclizumab (marketed under the brand name Zinbryta?) was a humanized monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). It functioned as an interleukin-2 (IL-2) receptor modulator, specifically designed to target a key pathway involved in aberrant T-cell activation, which is central to the autoimmune attack on the central nervous system in MS. It was administered via monthly subcutaneous injection. However, due to serious safety concerns¡ªincluding severe liver injury, immune-mediated disorders, and reports of encephalitis¡ªthe drug was voluntarily withdrawn worldwide from the market in 2018.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Daclizumab (Biosimilar Reference Antibody) (IL2RA)-RA0375-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.